JP7150740B2 - ｓＧＣ刺激薬による中枢神経系疾患の治療 - Google Patents

ｓＧＣ刺激薬による中枢神経系疾患の治療 Download PDF

Info

Publication number
JP7150740B2
JP7150740B2 JP2019545723A JP2019545723A JP7150740B2 JP 7150740 B2 JP7150740 B2 JP 7150740B2 JP 2019545723 A JP2019545723 A JP 2019545723A JP 2019545723 A JP2019545723 A JP 2019545723A JP 7150740 B2 JP7150740 B2 JP 7150740B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
compounds
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019545723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534327A5 (enExample
JP2019534327A (ja
Inventor
チュン，ジュン
リー，トーマス・ワイ－ホー
アイアンガー，ラジェシュ・アール
パール，ニコラス・ロバート
ジェルマーノ，ピーター
リバデネイラ，マリア・ディー
タン，キム
Original Assignee
サイクレリオン・セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイクレリオン・セラピューティクス，インコーポレーテッド filed Critical サイクレリオン・セラピューティクス，インコーポレーテッド
Publication of JP2019534327A publication Critical patent/JP2019534327A/ja
Publication of JP2019534327A5 publication Critical patent/JP2019534327A5/ja
Priority to JP2022126467A priority Critical patent/JP2022160605A/ja
Application granted granted Critical
Publication of JP7150740B2 publication Critical patent/JP7150740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019545723A 2016-11-08 2017-11-07 ｓＧＣ刺激薬による中枢神経系疾患の治療 Active JP7150740B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022126467A JP2022160605A (ja) 2016-11-08 2022-08-08 ｓＧＣ刺激薬による中枢神経系疾患の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419059P 2016-11-08 2016-11-08
US62/419,059 2016-11-08
PCT/US2017/060299 WO2018089328A1 (en) 2016-11-08 2017-11-07 Treatment of cns diseases with sgc stimulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022126467A Division JP2022160605A (ja) 2016-11-08 2022-08-08 ｓＧＣ刺激薬による中枢神経系疾患の治療

Publications (3)

Publication Number Publication Date
JP2019534327A JP2019534327A (ja) 2019-11-28
JP2019534327A5 JP2019534327A5 (enExample) 2020-12-17
JP7150740B2 true JP7150740B2 (ja) 2022-10-11

Family

ID=60452769

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019545723A Active JP7150740B2 (ja) 2016-11-08 2017-11-07 ｓＧＣ刺激薬による中枢神経系疾患の治療
JP2022126467A Pending JP2022160605A (ja) 2016-11-08 2022-08-08 ｓＧＣ刺激薬による中枢神経系疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022126467A Pending JP2022160605A (ja) 2016-11-08 2022-08-08 ｓＧＣ刺激薬による中枢神経系疾患の治療

Country Status (19)

Country Link
US (3) US11690828B2 (enExample)
EP (1) EP3538096B1 (enExample)
JP (2) JP7150740B2 (enExample)
KR (1) KR102475124B1 (enExample)
CN (1) CN110267658B (enExample)
AU (2) AU2017359018C1 (enExample)
BR (1) BR112019009449A2 (enExample)
CA (1) CA3042548A1 (enExample)
CL (1) CL2019001256A1 (enExample)
EA (1) EA201991147A1 (enExample)
ES (1) ES2972711T3 (enExample)
IL (1) IL266275B2 (enExample)
MA (1) MA46752A (enExample)
MX (2) MX2019005342A (enExample)
NZ (1) NZ753434A (enExample)
PH (1) PH12019501016A1 (enExample)
SG (1) SG10202104865UA (enExample)
TW (1) TWI812601B (enExample)
WO (1) WO2018089328A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538520B1 (en) * 2016-11-08 2025-12-31 Tisento Therapeutics Inc. CGS STIMULATORS
US11389449B2 (en) 2017-09-14 2022-07-19 Cyclerion Therapeutics, Inc. Treatment of metabolic syndrome with an sGC stimulator
CA3103676A1 (en) 2018-07-11 2020-01-16 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of mitochonrial disorders
US20220087970A1 (en) * 2019-01-18 2022-03-24 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
WO2021111419A1 (en) * 2019-12-05 2021-06-10 Cadila Healthcare Limited Modified release pharmaceutical compositions of riociguat
JP7412583B2 (ja) 2020-02-07 2024-01-12 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物
CN112924573B (zh) * 2021-01-21 2022-01-04 山东英盛生物技术有限公司 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法
US20250064799A1 (en) * 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
EP4658253A1 (en) * 2023-02-03 2025-12-10 R.P. Scherer Technologies, LLC Osmotic pharmaceutical capsules

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
DE3660408D1 (en) 1985-02-27 1988-08-25 Oerlikon Buehrle Ag Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
KR100634069B1 (ko) 1998-12-17 2006-10-16 알자 코포레이션 다중 코팅에 의한, 액체 충진 젤라틴 캡슐로부터 제어방출 시스템으로의 전환
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2534371A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
CA2711134A1 (en) 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
WO2010099054A2 (en) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2017106175A2 (en) * 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
ES2885003T3 (es) * 2016-09-02 2021-12-13 Cyclerion Therapeutics Inc Estimuladores de SGC fusionados bicíclicos

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2011年，Vol.21，p.6515-6518
European Journal of Neuroscience，2005年，Vol.21，p.1679-1688
European Journal of Pharmacology，2008年，Vol.590，p.233-240
Molecular Pharmacology，2003年，Vol.63, No.9，p.1322-1328

Also Published As

Publication number Publication date
MX2022010852A (es) 2022-09-27
WO2018089328A8 (en) 2019-03-28
TWI812601B (zh) 2023-08-21
AU2023270267A1 (en) 2023-12-07
NZ753434A (en) 2025-10-31
TW201822765A (zh) 2018-07-01
CN110267658B (zh) 2024-02-02
WO2018089328A1 (en) 2018-05-17
AU2017359018A1 (en) 2019-05-30
MA46752A (fr) 2019-09-18
EP3538096B1 (en) 2024-02-28
JP2022160605A (ja) 2022-10-19
US20250108040A1 (en) 2025-04-03
EP3538096C0 (en) 2024-02-28
CL2019001256A1 (es) 2019-10-04
KR102475124B1 (ko) 2022-12-08
CA3042548A1 (en) 2018-05-17
US20230381153A1 (en) 2023-11-30
IL266275A (en) 2019-06-30
ES2972711T3 (es) 2024-06-14
JP2019534327A (ja) 2019-11-28
AU2017359018B2 (en) 2023-08-31
AU2017359018C1 (en) 2023-12-21
MX2019005342A (es) 2019-10-02
KR20190094167A (ko) 2019-08-12
SG10202104865UA (en) 2021-06-29
EA201991147A1 (ru) 2019-11-29
EP3538096A1 (en) 2019-09-18
US20190343813A1 (en) 2019-11-14
CN110267658A (zh) 2019-09-20
IL266275B2 (en) 2023-12-01
BR112019009449A2 (pt) 2019-07-30
US11690828B2 (en) 2023-07-04
PH12019501016A1 (en) 2019-09-09
IL266275B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
JP7628096B2 (ja) 縮合二環式ｓｇｃ刺激剤
JP7150740B2 (ja) ｓＧＣ刺激薬による中枢神経系疾患の治療
US20260000653A1 (en) TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
EA041012B1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
HK40013531A (en) Treatment of cns diseases with sgc stimulators
HK40013531B (en) Treatment of cns diseases with sgc stimulators
BR112019004468B1 (pt) Estimulantes de sgc

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220808

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220817

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220928

R150 Certificate of patent or registration of utility model

Ref document number: 7150740

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250